Shares of hVIVO plc (LON:HVO – Get Free Report) fell 6.8% on Thursday . The stock traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). 2,518,262 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Price Performance
The firm has a market capitalization of £129.95 million, a PE ratio of 636.67 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The business’s 50 day moving average is GBX 23.20 and its two-hundred day moving average is GBX 26.66.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Are Penny Stocks a Good Fit for Your Portfolio?
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- How to Capture the Benefits of Dividend Increases
- Nebius Group: The Rising Star in AI Infrastructure
- What is a Special Dividend?
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
